Drug Safety, Part D Reimbursement Elevate Biotech Venture Capital Risk, Fund Manager Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased risks could result in lower valuations for biotech start-ups, Vector Fund Management Managing Director Phillips tells BIO annual meeting, which "makes it very, very hard for entrepreneurs to raise money." VC focus is shifting to less-risky, later-stage development, he says.
You may also be interested in...
Drug Safety Oversight Board Will Require Two-Thirds Majority For Recommendations
FDA's Drug Safety Oversight Board will need a two-thirds majority of a quorum to make recommendations, a Center for Drug Evaluation & Research Manual of Policies & Procedures states
Medicare Rx Plans Likely To Focus On Managing Use Of Low-Cost Drugs, AEI Rep Says
Because catastrophic drug costs will be picked up by the government under Part D, private Medicare drug plans may have little incentive to manage use of high-cost biotech products, American Enterprise Institute Resident Fellow Gottlieb says. However, high government spending eventually could lead to political backlash.
Biotech Industry Not Immune To Drug Safety Concerns, Genentech CEO Says
Biogen Idec's and Elan's suspension of Tysabri shows the biotech industry is susceptible to the safety debate, Genentech's Levinson says. The T-cell blocker Raptiva has a different mechanism of action than Tysabri and has a clean safety database, Genentech notes.